Pharmaceutical - Abbott Laboratories

Filter

Current filters:

Abbott Laboratories

Popular Filters

1 to 25 of 58 results

Abbott to acquire Russia’s Veropharm for up to $495 million

Abbott to acquire Russia’s Veropharm for up to $495 million

24-06-2014

US drugmaker Abbott yesterday confirmed it had reached a definitive agreement to acquire Veropharm, a…

Abbott LaboratoriesMergers & AcquisitionsPharmaceuticalProductionRussiaVeropharm

Bayer explores Russian options in the context of Pharma 2020 strategy

Bayer explores Russian options in the context of Pharma 2020 strategy

28-05-2014

Bayer HealthCare, one of the business units of German drug major Bayer, is exploring all options for…

Abbott LaboratoriesBayerGermanyHealthcareManufacturing plantOzonPharmaceuticalPharmaceutical drugPharmacologyPoliticsRussia

India’s patents moves could see particular uncertainty for diabetes sector

India’s patents moves could see particular uncertainty for diabetes sector

17-02-2014

The Indian government's decision to review patented drugs by multinationals, to allow for the manufacture…

Abbott LaboratoriesAsia-PacificDiabetesEli LillyIndiaMarkets & MarketingMerck & CoNovo NordiskPatentsPharmaceutical

New Zealand to fully subsidize Abbott Lab’s Ferrograd

New Zealand to fully subsidize Abbott Lab’s Ferrograd

06-01-2014

New Zealand’s Pharmaceutical Management Agency PHARMAC has approved an agreement with the local subsidiary…

Abbott LaboratoriesAsia-PacificFerrogradFinancialHematologyPharmaceutical

AHF sues Abbott and AbbVie for overcharging on AIDS drug pricing

AHF sues Abbott and AbbVie for overcharging on AIDS drug pricing

28-11-2013

In further legal action against drugmakers allegedly over pricing AIDS drugs in the USA, the AIDS Healthcare…

Abbott LaboratoriesAbbVieAnti-viralsKaletra TabletsLegalNorth AmericaNorvirPharmaceuticalPricing

Abbott Labs beats forecasts, despite China woes

Abbott Labs beats forecasts, despite China woes

16-10-2013

Abbott Laboratories, which last year spun off its research-based prescription medicines into AbbVie,…

Abbott LaboratoriesFinancialPharmaceutical

Agreements for influenza vaccine approved in New Zealand

15-10-2013

New Zealand’s PHARMAC has reached agreements with subsidiaries of GlaxoSmithKline and Abbott Laboratories…

Abbott LaboratoriesFluarixGlaxoSmithKlineHealthcareInfluvacNew ZealandPharmaceuticalPricingVaccines

New Zealand proposals for influenza vaccines

21-08-2013

New Zealand's Pharmaceutical Management Agency PHARMAC is seeking feedback on a proposal to list two…

Abbott LaboratoriesAsia-PacificFluarixGlaxoSmithKlineInfluvacPharmaceuticalPricingRegulationVaccines

US FDA warns pregnant women to not use valproate migraine prevention medicines

07-05-2013

The US Food and Drug Administration is alerting health care providers and patients that medications including…

Abbott LaboratoriesGenericsNeurologicalNorth AmericaNoven PharmaceuticalsPharmaceuticalRegulationSanofivalproate Sodium Injection

Leading Russian vaccines producer Petrovax acquired by Pharmstandard

07-05-2013

Russian drugmaker Pharmstandard is to acquire Petrovax Pharm, one of the country's largest producers…

Abbott LaboratoriesMergers & AcquisitionsPetrovax FarmPharmaceuticalPharmstandardVaccines

Positive Ph III results for AbbVie's Humira in pediatric Crohn's disease; five leukemia studies suspended

17-02-2013

AbbVie (NYSE: ABBV), the new spin-out from Abbott Laboratories, has announced the first long-term, patient-reported…

Abbott LaboratoriesAbbVieAnti-Arthritics/RheumaticsGastro-intestinalsHumiraOncologyPharmaceuticalResearch

AbbVie inaugural full-year outlook for 2013 in line with expectations

31-01-2013

Newly spun-out from Abbott Labs, research-based pharma company AbbVie (NYSE: ABB) yesterday confirmed…

Abbott LaboratoriesAbbVieFinancialPharmaceuticalResearch

Abbott Labs 4th-qtr net income plunges

23-01-2013

US health care major Abbott Laboratories (NYSE: ABT) posted sales of $10.84 billion for the fourth quarter…

Abbott LaboratoriesFinancialPharmaceutical

Abbott board prepares way for AbbVie split off

29-11-2012

US health care giant Abbott Laboratories (NYSE: ABT) says that its board of directors has approved the…

Abbott LaboratoriesAbbVieFinancialPharmaceutical

EU Commission approves Bayer's Eylea for wet AMD and Abbott's Humira for pediatric Crohn's

28-11-2012

There was good news yesterday for Germany's Bayer (BAYN: DE) and US health care major Abbott Laboratories…

Abbott LaboratoriesBayerEuropeEyleaGastro-intestinalsHumiraOphthalmicsPharmaceuticalRegeneronRegulation

Abbott launches Sucampo's Amitiza in Japan

27-11-2012

US drugmaker Sucampo Pharmaceuticals (Nasdaq: SCMP), and marketing partner health care major Abbott Laboratories…

Abbott LaboratoriesAmitizaAsia-PacificGastro-intestinalsMarkets & MarketingPharmaceuticalSucampo

Abbott presents new Humira data at ACR

12-11-2012

US pharma major Abbott Laboratories (NYSE: ABT) today announced results from a post-hoc analysis of its…

Abbott LaboratoriesAnti-Arthritics/RheumaticsHumiraPharmaceuticalResearch

Abbott Labs' AbbVie bond deal hit $37 billion yesterday, sources report

06-11-2012

US health care major Abbott Laboratories (NYSE: ABT) and its subsidiary AbbVie came to market early Monday…

Abbott LaboratoriesAbbVieFinancialPharmaceutical

Seattle Genetics and Abbott expand ADC collaboration

24-10-2012

Seattle Genetics and Abbott expand ADC collaboration

Abbott LaboratoriesBiotechnologyLicensingOncologyPharmaceuticalSeattle Genetics

1 to 25 of 58 results

Back to top